-
Novartis AG
-
Sector
Health Care
-
Industry
Pharmaceuticals
-
Company web
Link
-
Employees
Full Time Employees: 118,393
-
Executives
- Joerg Reinhardt
- Joseph Jimenez
- Enrico Vanni
- Harry Kirsch
- Michael Ball
- James Bradner
- Richard Francis
- Paul Hudson
- Bruno Strigini
- Felix Ehrat
-
Company address
- Lichtstrasse 35
- Basel, 4056
- Switzerland
- 1-41 61 324 1111
-
Investor Relation Site
Link
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Novartis AG: Slide deck
- NVS - Q3 Investor Presentation 24 Oct 2017: Slides deck
- NVS - Q3 Investor Presentation 25 Oct 2016: Slides deck
- NVS - Q2 Investor Presentation 18 July 2017: Slides deck
- NVS - Q2 Investor Presentation 19 July 2016: Slides deck
- NVS - Q1 Investor Presentation 25 April 2017: Slides deck
- NVS - Q1 Investor Presentation 21 April 2016: Slides deck
- NVS - Q4 Investor Presentation 25 Jan 2017: Slides deck